Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869229 | 0.85 | KDM1A (0.53) | MEN1KMT2AMAPTSMN1; SMN2KDM1A | |
| SCHEMBL7875795 | 0.83 | KDM1A (0.50) | MEN1KMT2AMAPTSMN1; SMN2KDM1A | |
| SCHEMBL3362993 | 0.75 | KDM1A (0.43) | MEN1KMT2AMAPTSMN1; SMN2KDM1A | |
| SCHEMBL11703072 | 0.72 | KDM4E (0.51) | MEN1KMT2AMAPTSMN1; SMN2KDM1A | |
| SCHEMBL8206430 | 0.72 | KDM1A (0.44) | MEN1KMT2AMAPTSMN1; SMN2KDM1A | |
| SCHEMBL8212730 | 0.72 | KDM1A (0.50) | MEN1KMT2AMAPTSMN1; SMN2KDM1A | |
| SCHEMBL10979565 | 0.71 | MAPT (0.58) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL7869236 | 0.71 | KDM1A (0.48) | KMT2AMAPTSMN1; SMN2KDM1ALMNA | |
| SCHEMBL11703495 | 0.70 | HTR3A (0.52) | MEN1KMT2AMAPTSMN1; SMN2KDM1A | |
| SCHEMBL4163642 | 0.70 | KDM4E (0.72) | MEN1KMT2AMAPTSMN1; SMN2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | MEN1 3638/4885KMT2A 1108/4885MAPT 1527/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | MEN1 4701/4885KMT2A 2353/4885MAPT 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.